Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | VNN1 | O95497 | 11/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.49 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.49 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL60691 | 0.93 | GSK3B (0.62) | GSK3BMRGPRX4XDHSLC22A12 | |
| SCHEMBL29441888 | 0.93 | GSK3B (0.62) | GSK3BMRGPRX4XDHSLC22A12 | |
| SCHEMBL27820119 | 0.91 | GSK3B (0.61) | GSK3BMRGPRX4XDHSLC22A12 | |
| Hydrochloric Acid SCHEMBL2031438 | 0.91 | GSK3B (0.61) | GSK3BMRGPRX4XDHSLC22A12 | |
| SCHEMBL11706688 | 0.91 | GSK3B (0.61) | GSK3BMRGPRX4XDHSLC22A12 | |
| SCHEMBL27804665 | 0.91 | GSK3B (0.61) | GSK3BMRGPRX4XDHSLC22A12 | |
| SCHEMBL4201889 | 0.89 | ATM (0.63) | GSK3BVNN1ATMTDP1L3MBTL1 | |
| SCHEMBL766131 | 0.82 | ATM (0.76) | ATMTDP1L3MBTL1 | |
| SCHEMBL11832713 | 0.82 | PTGS1 (0.57) | GSK3BVNN1ATMTDP1L3MBTL1 | |
| SCHEMBL5529069 | 0.82 | XDH (0.62) | GSK3BXDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072866-A1 | Process for preparation of cyanophenylbenzoic acid derivatives | TEIJIN LIMITED (JP) | 2004-04-15 | — | — | US | claimed |
| EP-1361213-A1 | PROCESS FOR PREPARATION OF CYANOPHENYLBENZOIC ACID DERIVATIVES | TEIJIN LIMITED (JP) | 2003-11-12 | — | — | EP | claimed |
| US-20040072866-A1 | Process for preparation of cyanophenylbenzoic acid derivatives | TEIJIN LIMITED (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1361213-A1 | PROCESS FOR PREPARATION OF CYANOPHENYLBENZOIC ACID DERIVATIVES | TEIJIN LIMITED (JP) | 2003-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072866-A1 | Process for preparation of cyanophenylbenzoic acid derivatives | CCNY, ACLY, IWS1 | GSK3B 3177/4885VNN1 3555/4885ATM 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.